CASTLE BIOSCIENCES, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
CASTLE BIOSCIENCES, INC. (CSTL) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2021-05-10
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2020-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2020-03-31 was 27.00K shares.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2019-09-30 was 67.00K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-10 | ||
| 2020-09-30 | 0.00 shares 10-Q · filed 2020-11-09 | 0.00 shares 10-Q · filed 2020-11-09 | |
| 2020-03-31 | 27.00K shares 10-Q · filed 2021-05-10 | ||
| 2019-09-30 | 67.00K shares 10-Q · filed 2020-11-09 | 66.80K shares 10-Q · filed 2019-11-12 | 0.00 shares 10-Q · filed 2020-11-09 |
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-11 | ||
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-12 | 0.00 shares 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |